Kenneth Efird will oversee Nobilis Health Corp.'s (HLTH:NYSE; NHC:TSX) operating units across the nation, focusing on execution of the company's strategic plan, according to a press release issued on July 11. Prior to stepping in as president, Efird had served as chief operating officer and chief business development officer at Nobilis, which operates surgical hospitals, physician practices and ambulatory surgical centers in Texas and Phoenix.
Since coming on board in 2005, Efird has overseen various aspects of the company's business, including clinical operations, sales and "the rollout of a new marketing strategy, which includes the integration of Athas technologies and the expansion of Nobilis' portfolio of brands," according to the company.
Neil Maruoka, an analyst with Canaccord Genuity who initiated coverage on Nobilis on July 13, pointed out that Athas, the company's "marketing arm," is "a key differentiator and organic growth engine. . .Through its targeted marketing, we believe that Athas has the ability to drive higher case volumes and higher revenue per procedure through Nobilis' facilities."
Canaccord also views Nobilis' surgical facilities "to be steady businesses, providing strong cash generation to underpin our valuation." Maruoka has a rated Nobilis a Buy with a price target of $4.50 per share.
Nobilis (then Northstar Health) acquired Athas Health, a Dallas-based marketing firm, in late 2014. The Athas technology, according to analyst William Sutherland of Emerging Growth Equities, provides Nobilis with an "end-to-end concierge model that begins with direct-to-consumer marketing through post-surgical support."
Back in May, analyst Dana Hambly of Stephens noted that Nobilis' recently launched subsidiary Concertis, a platform that "negotiates bundled payments for surgical procedures with payers covering pre- and post-operative services. . .should start driving case growth in [H2], improving on already solid organic growth."
According to Nobilis, Efird has "played a significant role in the integration of acquisitions," which included three new facilities in 2015 and the launch of Concertis.
"Throughout the past several years of tremendous growth, Kenneth has built an impressive track record of operational and strategic accomplishments," said company CEO Harry Fleming in the press release.
Read what other experts are saying about:
Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She owns, or her family owns, shares of the following companies mentioned in this interview: None.
2) The following companies mentioned in the article are sponsors of Streetwise Reports: Nobilis Health Corp. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific analysts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview until after it publishes.
One (Nobilis) Plus One (Athas) Equals Three
Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research [Neil Maruoka and Matt Bottomly] hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research.
Canaccord Genuity's up-to-date disclosures may be obtained here.
Emerging Growth Equities, Ltd., May 23, 2016
Nobilis Health Corp.
I, William Sutherland, certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. In addition, no part of my compensation was, is, or will be directly or indirectly related to this recommendation or views contained in this report.
•Emerging Growth Equities ("EGE") does not make a market in the securities issued by the subject company ("Company").
•EGE has not acted as a manager of in a public offering of securities for the Company within the last 12 months.
•EGE has not provided investment banking services or other advice to the Company, for which it received fees, within the last 12 months.
•EGE seeks investment banking assignments from a wide range of companies, including those on which the Firm provides research recommendations. Therefore, investors should assume that EGE intends to seek compensation for investment banking services within the next three months, and thereafter, from the Company.
•Neither the analyst nor a household member owns securities in the Company. Neither the analyst nor a household member is an officer, director or advisory board member of the Company.
•The Firm's analysts are compensated like other employees of EGE, based upon the Firm's overall revenue generation, which includes revenues from institutional sales and investment banking departments, as well as on various other activities performed by the Firm's analysts that are intended assist the Firm's institutional clients.
•EGE and/or its affiliates and employees may own securities issued by the Company from time to time.
Stephens Inc., May 12, 2016
Nobilis Health Corp.
The analyst primarily responsible for the preparation of the content of this report certifies that (i) all views expressed in this report accurately reflect the analyst's personal views about the subject company and securities, and (ii) no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the analyst in this report.
•The research analyst principally responsible for preparation of this report has received compensation that is based on the firm's overall revenue which includes investment banking revenue.
•Stephens Inc. maintains a market in the common stock of Nobilis Health Corp. as of the date of this report and may act as principal in these transactions.
•Stephens Inc. expects to receive or intends to seek compensation for investment banking services from Nobilis Health Corp. in the next three months.